NCT07006285

T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 38 (estimated)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure. In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations. The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation. The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.

Conditions

• Asthma
• Occupational Asthma
• Occupational Diseases

Interventions

Type	Name	Description
OTHER	Measure of T2 biomarkers	T2 Biomarkers are estimated via induced sputum: Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution. Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge

Timeline

• Start date: 2025-06-01
• Primary completion: 2025-06-01
• Completion: 2026-06-01
• First posted: 2025-06-05
• Last updated: 2025-06-05

Locations

1 site across 1 country: France